Immunohistochemical profiling of ALK fusion gene-positive adenocarcinomas of the lung

International Journal of Surgical Pathology

Volumn 21, Issue 5, 2013, Pages 476-482

  Sakai, Yasuhiro ^a   Nakai, Tokiko ^a   Ohbayashi, Chiho ^b   Imagawa, Naoko ^a   Yanagita, Emmy ^a   Satake, Rumiko ^c   Nitta, Atsushi ^c   Kajimoto, Kazuyoshi ^c   Sakuma, Toshiko ^c   Itoh, Tomoo ^a  

^a KOBE UNIVERSITY HOSPITAL   (Japan)

^b NARA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^c HYOGO CANCER CENTER   (Japan)

Author keywords

adenocarcinoma; ALK rearrangement; immunohistochemical profiling; non small cell lung cancer; squamous cell carcinoma; tissue microarray

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; DESMOCOLLIN; DESMOCOLLIN 3; DESMOGLEIN 3; NAPSIN A; PROTEIN P40; THYROID TRANSCRIPTION FACTOR 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; TISSUE MICROARRAY;

ADENOCARCINOMA; ALK REARRANGEMENT; IMMUNOHISTOCHEMICAL PROFILING; NON-SMALL-CELL LUNG CANCER; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; ONCOGENE PROTEINS, FUSION; RECEPTOR PROTEIN-TYROSINE KINASES; TISSUE ARRAY ANALYSIS;

EID: 84884685296     PISSN: 10668969     EISSN: 19402465     Source Type: Journal    
DOI: 10.1177/1066896913489345     Document Type: Article

References (39)

1. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 ; 26: 3543-3551
2. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004 ; 22: 2184-2191
3. Rossi G, Pelosi G, Graziano P, Barbareschi M, Papotti M. A reevaluation of the clinical significance of histological subtyping of non-small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol. 2009 ; 17: 206-218
4. Ring BZ, Seitz RS, Beck RA, et al. A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol. 2009 ; 22: 1032-1043
5. Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and p63, and EGFR mutation analysis. J Thorac Oncol. 2010 ; 5: 436-441
6. Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol. 2011 ; 24: 1348-1359
7. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol. 2011 ; 35: 15-25
8. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer. 2011 ; 117: 3416-3423
9. Pelosi G, Rossi G, Bianchi F, et al. Immunohistochemistry by means of widely agreed-upon markers (cytokeratin 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol. 2011 ; 6: 1039-1049
10. Tsuta K, Tanabe Y, Yoshida A, et al. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the lung. J Thorac Oncol. 2011 ; 6: 1190-1199
11. Ocque R, Tochigi N, Ohori NP, Dacic S. Usefulness of immunohistochemical and histochemical studies in the classification of lung adenocarcinoma and squamous cell carcinoma in cytologic specimens. Am J Clin Pathol. 2011 ; 136: 81-87
12. Yanagita E, Imagawa N, Ohbayashi C, Itoh T. Rapid multiplex immunohistochemistry using the 4-antibody cocktail YANA-4 in differentiating primary adenocarcinoma from squamous cell carcinoma of the lung. Appl Immunohistochem Mol Morphol. 2011 ; 19: 509-513
13. Aikawa E, Kawahara A, Hattori S, et al. Comparison of the expression levels of napsin A, thyroid transcription factor-1, and p63 in nonsmall cell lung cancer using cytocentrifuged bronchial brushings. Cancer Cytopathol. 2011 ; 119: 335-345
14. Roh MH, Schmidt L, Placido J, et al. The application and diagnostic utility of immunocytochemistry on direct smears in the diagnosis of pulmonary adenocarcinoma and squamous cell carcinoma. Diagn Cytopathol. 2012 ; 40: 949-955
15. Noh S, Shim H. Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: a tissue microarray study of poorly differentiated areas. Lung Cancer. 2012 ; 76: 51-55
16. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology. 2002 ; 40: 403-439
17. Lyda MH, Weiss LM. Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. Hum Pathol. 2000 ; 31: 980-987
18. Cui T, Yang L, Mireskandari M, et al. The diagnostic value of cytokeratin 5/6, 14, 17, and 18 expression in human non-small cell lung cancer. Oncology. 2011 ; 80: 333-340
19. Angulo B, Suarez-Gauthier A, Lopez-Rios F, et al. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol. 2008 ; 214: 347-356
20. Monica V, Ceppi P, Righi L, et al. Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol. 2009 ; 22: 709-717
21. Savci-Heijink CD, Kosari F, Aubry MC, et al. The role of desmoglein-3 in the diagnosis of squamous cell carcinoma of the lung. Am J Pathol. 2009 ; 174: 1629-1637
22. Aqackiran Y, Ozcan A, Akyurek N, Memis L, Findik G, Kaya S. Desmoglein-3 and napsin A double stain, a useful immunohistochemical marker for differentiation of lung squamous cell carcinoma and adenocarcinoma from other subtypes. Appl Immunohistochem Mol Morphol. 2012 ; 20: 350-355
23. Tacha D, Yu C, Bremer R, Qi W, Haas T. A 6-antibody panel for the classification of lung adenocarcinoma versus squamous cell carcinoma. Appl Immunohistochem Mol Morphol. 2012 ; 20: 201-207
24. Nonaka D. A study of ΔNp63 expression in lung non-small cell carcinomas. Am J Surg Pathol. 2012 ; 36: 895-899
25. Pelosi G, Fabbri A, Bianchi F, et al. ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol. 2012 ; 7: 281-290
26. Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol. 2012 ; 25: 405-415
27. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007 ; 448: 561-566
28. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 ; 363: 1693-1703
29. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008 ; 3: 13-17
30. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol. 2009 ; 22: 508-515
31. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the Western population. Clin Cancer Res. 2009 ; 15: 5216-5223
32. Jokoji R, Yamasaki T, Minami S, et al. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol. 2010 ; 63: 1066-1070
33. Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol. 2011 ; 35: 1226-1234
34. Yamamoto M, Takeuchi K, Shimoji M, et al. Small non-mucinous bronchioloalveolar carcinoma with anaplastic lymphoma kinase immunoreactivity: a novel ALK fusion gene?. Cancer Sci. 2012 ; 103: 390-392
35. Chaft JE, Rekhtman N, Ladanyi M, Riely GJ. ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma. J Thorac Oncol. 2012 ; 7: 768-769
36. Klempner SJ, Cohen DW, Costa DB. ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers. J Thorac Oncol. 2011 ; 6: 1439-1440
37. Wong DW, Leung EL, So KK, et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer. 2009 ; 115: 1723-1733
38. Wong DW, Leung EL, Wong SK, et al. A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer. 2011 ; 117: 2709-2718
39. Togashi Y, Soda M, Sakata S, et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One. 2012 ; 7: e31323